Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...
The Super Bowl is always packed with attention-grabbing ads, but Novartis’s cleavage-packed commercial created particularly ...
Hosted on MSN9d
Novartis to buy Anthos Therapeutics in $3.1 bn dealSwiss pharmaceutical firm Novartis said on Tuesday that it has agreed to buy privately held, clinical-stage US biotech Anthos ...
Anthos was founded by Blackstone Life Sciences and Novartis in 2019 to develop, manufacture, and commercialize abelacimab, a ...
Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ...
Deutsche Bank raised its price target for Novartis by 10% to CHF110, based on 14x estimated 2025 earnings. The firm considers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback